Tarsus announces positive topline data of TP-03 from Saturn-2 Phase 3 trial, expects to file NDA later this yearMay 2nd 2022
TP-03 met the primary and all secondary endpoints, effectively resolved Demodex blepharitis and was well-tolerated with no serious treatment-related adverse events. 56% of patients on TP-03 achieved the primary endpoint of complete collarette cure.
VJCRGS issue celebrates ‘great lectures’ in ophthalmologyApril 11th 2022
Three prestigious lectures are featured, including Ehud Assia, MD, from Israel who gave the ESCRS Binkhorst Lecture; Richard Packard, MD, from England who gave the Choyce Lecture to the UKISCRS; and Michael Snyder, of the Cincinnati Eye Institute in Cincinnati, Ohio, USA, who delivered the Kelman Lecture at the 2021 American Academy of Ophthalmology meeting.
UCI-led study lays foundation for establishing base editing as a one-time, durable treatment for inherited retinal degenerationApril 7th 2022
According to researchers at the University of California, Irvine, base editing may provide long-lasting retinal protection and prevent vision deterioration in patients with inherited retinal degeneration, specifically in Leber congenital amaurosis patients.
Intensive multimodal therapy is effective for orbital retinoblastomaMarch 17th 2022
Investigators observe survival rate with orbital retinoblastoma improves substantially due to a combination approach that includes intensive sequential treatment comprised of chemotherapy, enucleation, and external beam radiation therapy.
Apellis announces longer-term data from Phase 3 DERBY and OAKS studies for geographic atrophyMarch 16th 2022
According to the company, pegcetacoplan demonstrated continuous and clinically meaningful effects at month 18 in the studies, which also found that treatment effects in DERBY were comparable to OAKS during months 6 to 18. The combined 18-month data show the potential for improving treatment effects over.
Ukrainian-born ophthalmologist staying positive for family remaining in war-torn countryMarch 16th 2022
Anton Vlasov, DO, moved to the United States in 2001 at the age of 14, but since Russia invaded his homeland last month, the safety of family still living in Ukraine has weighed heavy on his mind.
Study: Eyenovia delivery technology reduces conjunctival cell toxicity from preserved ophthalmic solutions to level comparable with non-preserved solutionMarch 15th 2022
The study, conducted with Tufts Medical Center, represents a breakthrough showing that Microdose Array Print technology can provide similar benefits of non-preserved medications.
Identifying 3 barriers keeping families from accessing cataract treatment for their children in IndiaMarch 14th 2022
Dr. Rishi Raj Borah, Country Director with Orbis India, discusses recent research he co-authored showing the top 3 barriers keeping families from accessing cataract treatment for their children in India.
Glaukos announces start of Phase II corneal health clinical program for pharmaceutical platformMarch 14th 2022
The company’s iLink therapy for the treatment of keratoconus consists of novel single-use drug formulations that are bio-activated by proprietary systems through the delivery of ultraviolet light to the cornea to induce corneal cross-linking designed to strengthen, stabilize and reshape the cornea.
Determining germline mutations in children with unilateral retinoblastomaMarch 14th 2022
Carol L. Shields, MD, and a group of colleagues conducted a retrospective case series to evaluate the likelihood of germline retinoblastoma in children with solitary unilateral retinoblastoma.
Real World Ophthalmology: Sharing knowledge, networking and secrets to success in early practiceMarch 11th 2022
Lisa M. Nijm, MD, JD, previews the program for this April 2 virtual event designed to help young ophthalmologists learn everything they need to know when starting practice.